C-type natriuretic peptide: a selective cardiovascular peptide

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Peptide Hormone Research

Background:

• Atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) are structurally related peptides with known physiological roles.
• Understanding the distinct in vivo actions of CNP compared to ANP is crucial for elucidating their roles in cardiovascular regulation.

Purpose of the Study:

• To compare the vasoactive and natriuretic effects of intravenous C-type natriuretic peptide (CNP) and atrial natriuretic peptide (ANP) in anesthetized dogs.
• To investigate the effects of intrarenal CNP administration.
• To determine the presence and form of circulating CNP in canine plasma.

Main Methods:

• Intravenous infusions of CNP and ANP at varying doses in anesthetized dogs (n=9 for IV studies).
• Intrarenal infusion of CNP in anesthetized dogs (n=5).
• Measurement of blood pressure, plasma guanosine 3',5'-cyclic monophosphate (cGMP) levels, and natriuresis.
• Detection and characterization of circulating CNP immunoreactivity using immunoassay and gel permeation chromatography.

Main Results:

• Intravenous CNP caused a greater decrease in blood pressure than ANP.
• CNP infusion was associated with a smaller increase in cGMP compared to ANP.
• Neither intravenous nor intrarenal CNP administration resulted in natriuresis, unlike ANP.
• CNP immunoreactivity was detected in canine plasma at low picomolar concentrations, corresponding to the 22-amino acid form.

Conclusions:

• CNP is a potent vasodilator in vivo, distinct from ANP's effects on blood pressure and natriuresis.
• Circulating CNP exists in canine plasma and may play a significant role in regulating vascular tone.
• CNP's actions are mediated through mechanisms that differ from those primarily associated with ANP and cGMP production.